Nasdaq · Biotech stocks database
GRFS (Grifols S.A.) stock: $7.31, $5.03B market cap, $969.4M cash, $4.44B EV, $5.03B fully diluted market cap. Next expected readout: Sep-27. Lead program: Alpha-1 15% (Alpha 1 Antitrypsin Deficiency), Phase 3. Data from Fully Diluted's biotech stocks database.
| Cash | $969.4M |
|---|---|
| Debt | $380.8M |
| Net cash | $588.6M |
| Enterprise value | $4,437.4M |
| Basic shares | 687.1M shares |
| Fully diluted shares | 687.6M shares |
| Fully diluted market cap | $5,026.0M |
| Cash per share | $1.41 |
Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.
Loading GRFS daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Now - Oct 24, 2026 | Alpha-1 MP | Phase 3 | Pulmonary Emphysema in Alpha-1 PI Deficiency | — |
| Jan 12 - Feb 23 | Albumin infusion (25% albumin) | Phase 2 | Cirrhosis; Ascites Hepatic | — |
| Nov 11 - Dec 23 | Alpha-1 15% | Phase 3 | Alpha 1 Antitrypsin Deficiency | — |
| Feb 11 - Mar 24 | Gamunex-C | Phase 3 | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | — |
| Oct 12 - Nov 23 | Gamunex-C, 10% Injectable Solution | Phase 3 | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphom | — |
| Oct 13 - Nov 24 | Alpha-1 MP | Phase 3 | Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | — |
| Jan 12 - Feb 23 | Plasma-derived AT-III concentrate | Phase 3 | Antithrombin III Deficiency | — |
| Sep 12 - Oct 24 | Xembify | Phase 3 | Hypogammaglobulinemia; Bacterial Infections; B-cell Chronic Lymphocytic Leukemia | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.